Clinical Trials Browser

OTHER × Prostatic Neoplasms × darolutamide × Clear all

NCT04070209 2026-05-27

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04136353 2026-05-06

DASL-HiCaP

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04925648 2026-04-23

PICASSO

Phase 2 Completed

Prostatic Neoplasms

NCT06378866 2026-04-20

DIVINE

Phase 2 Recruiting

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT07027124 2026-03-19

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07428642 2026-03-18

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Prostatic Neoplasms

NCT07476677 2026-03-17

ANDARP

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Phase 2 Recruiting

Prostatic Neoplasms

NCT06463457 2026-03-09

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05683964 2026-02-13

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT04558866 2026-02-12

ExBAT

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06627530 2026-02-11

COAction

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Phase 1 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Phase 4 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07282197 2025-12-15

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04335682 2025-11-04

ARACOG

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07172685 2025-09-15

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Phase NA Recruiting

Prostatic Neoplasms

NCT04319783 2025-08-21

DECREASE

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06625970 2025-06-26

PEACE 7

Phase 3 Recruiting

Prostatic Neoplasms

NCT06652607 2025-03-12

PSA-DEEP02

Neoplasm Metastasis, Prostatic Neoplasms

NCT06575257 2024-08-28

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT06473259 2024-06-25

ECHOS

Neoplasm Metastasis, Prostatic Neoplasms

NCT06435702 2024-05-30

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Not yet recruiting

Prostatic Neoplasms

NCT06430411 2024-05-28

OLIGOMET

Not yet recruiting

Prostatic Neoplasms

NCT02933801 2024-03-13

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2 Terminated

Prostatic Neoplasms

NCT05116475 2024-03-12

ALADDIN

Phase 3 Recruiting

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04641078 2024-02-28

DART

Phase 2 Unknown

Neoplasm Metastasis, Prostatic Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

Phase 2 Not yet recruiting

BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

NCT06177015 2023-12-26

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Phase 3 Recruiting

Prostatic Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

NCT05771896 2023-09-14

CARE

Phase 3 Withdrawn

Prostatic Neoplasms

NCT05900973 2023-08-07

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

Phase 2 Unknown

Prostatic Neoplasms

NCT05249712 2023-01-03

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

Phase 2 Unknown

Prostatic Neoplasms